Minitide

# Minitide ## Overview - **Classification**: Alpha-1 Adrenergic Antagonist - **Mechanism**: Selectively blocks alpha-1 adrenergic receptors in vascular smooth muscle and prostate, leading to vasodilation and relaxation of prostatic smooth muscle. ## Primary Indications 1. **Benign Prostatic Hyperplasia (BPH)** - Symptomatic relief of urinary outflow obstruction. 2. **Hypertension (HTN)** - Management of essential hypertension, often as add-on therapy. ## Adult Dosing ### Standard Dosing **Benign Prostatic Hyperplasia (BPH)** - **Dose**: Start with **1 mg** - **Frequency**: Once daily **at bedtime** - **Route**: Oral - **Duration**: Chronic - **Titration**: May increase to **2 mg**, then **5 mg**, then **10 mg** once daily based on response and tolerability, at 1-2 week intervals. Max **20 mg daily**. **Hypertension (HTN)** - **Dose**: Start with **1 mg** - **Frequency**: Two to three times daily (BID-TID) - **Route**: Oral - **Duration**: Chronic - **Titration**: May increase to **2 mg**, then **5 mg**, then **10 mg** two to three times daily based on response and tolerability. Max **20 mg daily**. ### Dose Adjustments - **Renal Impairment**: No specific dose adjustment for mild-moderate. Use caution in CrCl < 30 mL/min; start **1 mg once daily**, titrate slowly. - **Hepatic Impairment**: Use caution in severe hepatic impairment. Start **1 mg once daily** and monitor closely. - **Elderly Patients**: Increased risk of orthostatic hypotension. Start with **1 mg once daily at bedtime** and titrate very slowly. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Not routinely recommended. - **Frequency**: N/A - **Maximum**: N/A - **Special Notes**: Use only for compelling, refractory hypertension under specialist supervision; dose not established. ### Infants (1-12 months) - **Dose**: Not routinely recommended. - **Frequency**: N/A - **Maximum**: N/A - **Special Notes**: Use for refractory hypertension only, under specialist supervision. Dose not well-established. ### Children (1-12 years) - **Dose**: For hypertension, start **0.05 mg/kg/dose**. - **Frequency**: Every 8-12 hours (BID-TID) - **Maximum**: **0.25 mg/kg/dose** or **2.5 mg/dose**, whichever is less. Maximum total daily dose **10 mg/day**. ### Adolescents (13-18 years) - **Dose**: Start with **1 mg** - **Frequency**: Once daily (for BPH) or BID (for HTN), similar to adult initiation. - **Maximum**: **20 mg daily** (adult maximum). - **Special Notes**: Titrate carefully due to potential for orthostatic hypotension. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Minitide or other quinazoline derivatives. - **Absolute**: History of orthostatic hypotension with syncope. - **Relative**: Concurrent use of PDE5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. ### Common Adverse Effects - **Very Common (>10%)**: Dizziness, orthostatic hypotension (especially "first-dose phenomenon"), headache. - **Common (1-10%)**: Fatigue, palpitations, nasal congestion, nausea. - **Serious but Rare**: Priapism (prolonged erection), syncope, severe hypotension. ### Key Drug Interactions - **Phosphodiesterase-5 (PDE5) Inhibitors**: Potentiates hypotensive effects. Administer PDE5 inhibitors cautiously and at least 4-6 hours after Minitide. - **Other Antihypertensives**: Additive hypotensive effects. Monitor blood pressure closely; may require dose reduction of other agents. - **NSAIDs**: May reduce antihypertensive effect of Minitide due to fluid retention. Monitor BP. ## Monitoring & Follow-up - **Before Treatment**: Baseline supine and standing blood pressure. Consider prostate-specific antigen (PSA) for BPH. - **During Treatment**: Monitor supine and standing BP regularly (e.g., 2-4 weeks after initiation/dose change). Assess BPH symptom improvement (AUA score). - **Clinical Signs**: Watch for dizziness, lightheadedness, syncope, especially upon standing. Counsel on priapism. ## Clinical Pearls - 💡 **Tip 1**: Administer the **first dose at bedtime** to minimize "first-dose" orthostatic hypotension. - 💡 **Tip 2**: Counsel patients to avoid sudden changes in position (e.g., standing quickly from sitting/lying) to prevent dizziness. - 💡 **Tip 3**: Minitide helps symptoms of BPH but does not reduce prostate size. - 💡 **Tip 4**: Inform patients about the rare but serious risk of priapism and to seek immediate medical attention if it occurs. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.